Vivebiotech Secures Investment from Ampersand Capital Partners

Gómez-Acebo & Pombo has advised Boston-based private equity firm Ampersand Capital Partners on their strategic investment in Vivebiotech, a Spanish biotechnology company specializing in the development of viral vectors for rare diseases and cancer. This partnership aims to significantly enhance Vivebiotech’s manufacturing capabilities for lentiviral vectors, which are crucial in the cutting-edge field of gene and cell therapies. The investment is expected to support several pioneering client projects with a focus on innovative therapies administered in vivo (within the body) and ex vivo (outside the body). The involvement of Ampersand, noted for its specialization in the life sciences and healthcare sectors, represents a promising advancement in the execution of Vivebiotech’s growth strategy. Gómez-Acebo & Pombo’s extensive advisory team spanned several legal domains including corporate, tax, public law, labor, intellectual property, and competition, highlighting the complex, multifaceted nature of the investment. Given the focus on developing solutions for rare medical conditions, this investment underscores the growing importance of biotech innovations in addressing unmet medical needs globally.